Press and Public Relations

Joint International Journal of Cancer and Klaus Tschira Stiftung Lecture at DKFZ

Wednesday, March 28, 2012 - Harold Moses, M.D.

Dr. Moses received his M.D. degree at Vanderbilt University in 1962, specializing in pathology and receiving a professorship in that field at Vanderbilt. The next steps in his career took him to the U.S. Dept. of Public Health and NIH, back to Vanderbilt, and then to the Mayo Clinic in Minnesota. In 1985 he returned to Vanderbilt as chairman of the Dept. of Cell Biology, where he has worked in various capacities ever since. Importantly, he was Director of the Vanderbilt-Ingram Cancer Center from 1993 to 2005 and has been serving as Director Emeritus, Vanderbilt-Ingram Comprehensive Cancer Center since 2005.

Moses’ major research interests are growth factors, in particular TGF-beta, oncogenes, growth inhibitors, and tumor suppressor genes. He has investigated the critical role of stroma in cancer initiation and progression. At his laboratory, he genetically modified the TGF-beta receptor in mice to more closely examine the roles of TGF-beta signaling in cancer. His findings support the hypothesis that epithelial cell autonomous TGF-beta signaling is tumor suppressive in both early and late stages of carcinogenesis. Data also indicate that TGF-beta signaling is a major regulator of chemokine secretion and resultant bone marrow cell infiltration and that targeting pathways that inhibit bone marrow cell differentiation or chemokine receptors may be useful in both therapy and prevention of cancer. He is also one of the pioneers in elucidating the role of the tumor microenvironment in cancer progression.

Harold Moses has served as editor and on the boards of the top journals in the field. He is a highly sought after speaker and author of over 300 peer-reviewed publications. A long list of honors documents a very distinguished career.

Interview

Harold L. Moses, M.D. interviewed by Dr. Stefanie Seltmann

to top